



**Supplemental Figure 10. Effect of myostatin/ActRIIB signaling on muscle phenotype.**

**(a,d)** 2-months-old *mdx* mice were systemically treated for 4 months with sActRIIB-Fc or PBS ( $n=5$  for each condition). **(a)** Cross section of the *soleus* muscle from *mdx* mice treated with PBS (upper images) or sActRIIB-Fc (lower images), sectioned at mid belly level and stained with H&E. Sections depict muscle fibers with central nucleation, cellular infiltrates, endomysial fibrosis, and muscle fiber necrosis (arrows) (left images) as well as regenerating muscle fibers (arrowheads) (right images). **(b)** Serum creatine kinase levels after 4 months of treatment with sActRIIB-Fc in comparison to PBS-treated *mdx* mice ( $n=5$  for each condition). **(c,d)** The histograms depict the cross sectional areas of muscle fibers from **(c)** *EDL* muscles and **(d)** *soleus* muscles after 4 months of treatment with sActRIIB-Fc in comparison to PBS-treated *mdx* mice. Values are shown as means  $\pm$  SEM.  $p$ -Values were calculated using the nonparametric *U*-Test. CSA, cross sectional area.